Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States.
The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.34 Decreased by -13.33% | -0.30 Decreased by -13.33% |
| Feb 13, 24 | -0.27 Decreased by -3.85% | -0.30 Increased by +10.00% |
| Nov 13, 23 | -0.28 Decreased by -47.37% | -0.28 |
| Sep 14, 23 | -0.25 Increased by +32.43% | -0.36 Increased by +30.56% |
| May 11, 23 | -0.30 Increased by +53.85% | -0.30 |
| Feb 10, 23 | -0.26 Increased by +67.50% | -0.32 Increased by +18.75% |
| Nov 9, 22 | -0.19 Increased by +79.35% | -0.38 Increased by +50.00% |
| Sep 15, 22 | -0.37 Increased by +52.56% | -0.41 Increased by +9.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | N/A Decreased by N/A% | -17.05 M Decreased by -8.70% | - - |
| Dec 31, 23 | 0.00 Decreased by N/A% | -13.91 M Decreased by -2.51% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.52 M Decreased by -47.54% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -12.73 M Decreased by -78.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -15.69 M Decreased by -39.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -13.57 M Decreased by -7.75% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -9.84 M Decreased by -25.63% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -7.14 M Decreased by -9.95% | Decreased by N/A% Decreased by N/A% |